Key result
JK07 reduced interstitial fibrosis, increased capillary density, and induced reparative cardiac transcriptional responses peaking 1 day post-treatment in mice with LVEF <40%.
Why the study?
Does the ErbB4 agonist JK07 improve cardiac structure and activate reparative cellular pathways in a murine myocardial infarction-induced HFrEF model?
Does the ErbB4 agonist JK07 improve cardiac structure and activate reparative cellular pathways in a murine myocardial infarction-induced HFrEF model?
In a murine HFrEF model, preferential ErbB4 activation via JK07 reduced fibrosis, increased capillary density, and activated reparative transcriptional pathways across multiple cardiac cell types.
Answers are grounded in this paper and cite their sources.
JK07 supports selective ErbB4 activation in murine post-MI HF; leaves open clinical translation and human efficacy.
Selective activation of the neuregulin-1 (NRG-1)/ErbB pathway is a promising strategy for cardiac repair in heart failure (HF), but recombinant NRG-1 therapies are limited by poor stability and nonselective receptor activation. JK07 is a novel biologic that combines the epidermal growth factor-like domain of NRG-1 with an ErbB3-antagonist antibody, enabling preferential ErbB4 activation. In a murine myocardial infarction-induced HF model (left ventricular ejection fraction <40%), mice received single or repeated doses of JK07 (1 mg/kg) or vehicle. Cardiac structure and cellular responses were assessed using echocardiography, histology, and single-nucleus RNA sequencing. JK07 reduced interstitial fibrosis and increased capillary density while inducing robust, transient, cell-specific transcriptional responses, most pronounced 1 day after treatment. Cardiomyocytes showed enhanced ErbB4 expression and metabolic pathways, fibroblasts adopted reparative phenotypes, and endothelial cells exhibited transient angiogenic activation. JK07 also preserved mitochondrial respiration in cardiomyocytes under inflammatory stress, supporting ErbB4 activation as a potential therapeutic strategy for HF.
No takes yet. Share an insight, caveat, or question.
Civati et al. (2026) studied Heart failure with reduced ejection fraction (murine MI-induced HF model). JK07 (ErbB4 agonist) vs. Vehicle was evaluated on Cardiac structure (interstitial fibrosis, capillary density) and cell-specific transcriptional responses. JK07 reduced interstitial fibrosis, increased capillary density, and induced reparative cardiac transcriptional responses peaking 1 day post-treatment in mice with LVEF <40%.
Synapse has enriched 10 related papers. Consider them for comparative context: